

Technology Advisory Committee B Interests Register

Secukinumab for treating moderate to severe hidradenitis suppurativa [ID4039]

Publication Date: 18/10/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Warren Linley	TAC B member	Direct – Financial	Warren was cost lead for the appraisal of secukinumab [ID4039]. He declared an interest based on the fact he holds shares in Amgen, which is listed as a potential comparator company. The Chair of TAC B considered his declaration and concluded that he could still be the cost lead for this appraisal (the company's positioning of secukinumab effectively excludes Amgen's product as a comparator). He declared this for transparency.	24/05/2023	N/A	It was agreed that Warren's declaration would not prevent him from participating in discussions on this appraisal.
Peter Wheatley Price	TAC B committee member	Direct – Financial	Takeda manufacture ixazomib which is used in combination with lenalidomide and dexamethasone for treating	30/05/2023	N/A	It was agreed that Peters declaration would prevent him from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			relapsed or refractory multiple myeloma (TA505). We have just successfully exited the CDF (ID1635). Although it is different line, the use of DRd in NDMM will direct impact the treatment pathway downstream. Propose do not participate			discussions on this appraisal.
Charles Crawley	TAC B Chair	Direct - Personal	Charles' clinical practice includes people with myeloma.	31/05/2023	N/A	It was agreed that Charles's declaration would not prevent him from participating in discussions on this appraisal.
Dr John Ingram	Clinical Reader & Consultant Dermatologist at Cardiff University	Direct – Financial	John is a consultant for Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, and UCB Pharma and has served on advisory boards for Insmad, Kymera Therapeutics and Viela Bio, all in the field of HS. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient	30/04/2023	N/A	It was agreed that John's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Global Assessment instruments for HS. Dr Ingram receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate.			
Dr John Ingram	Clinical Reader & Consultant Dermatologist at Cardiff University	Direct – Non-Financial	Officer of British Association of Dermatologists. Medical Adviser to HS Trust.	30/04/2023	N/A	It was agreed that John's declaration would not prevent him from participating in discussions on this appraisal.
Dr John Ingram	Clinical Reader & Consultant Dermatologist at Cardiff University	Indirect - Financial	John's department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments.	30/04/2023		It was agreed that John's declaration would not prevent him from participating in discussions on this appraisal.
Dr John Ingram	Clinical Expert	Direct – financial	Dr Ingram is a consultant for Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, and UCB Pharma and has served on advisory boards for Insmmed, Kymera	02/08/2023	N/A	It was agreed that John's declaration would not prevent him from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			Therapeutics and Viela Bio, all in the field of HS. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS. Dr Ingram receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate.			discussions on this appraisal.
Dr John Ingram	Clinical Expert	Direct – non-financial	Officer of British Association of Dermatologists. Medical Adviser to HS Trust.	02/08/2023	N/A	It was agreed that John's declaration would not prevent him from participating in discussions on this appraisal.
Dr John Ingram	Clinical Expert	Indirect	Dr Ingram's department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments.	02/08/2023	N/A	It was agreed that John's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Ruth Lamb	Consultant Dermatologist, St Georges University Hospital NHS Foundation Trust	Direct – Financial	<p>Ruth has received honoraria x1 for involvement in a virtual advisory board with Novartis (regarding discussion around problems with all/any current treatments in hidradenitis suppurativa with no particular reference to Secukinumab) on one occasion in the last 12 months (May 2022).</p> <p>She has agreed provisionally to take part in a further global advisory panel for Novartis over the next 6 months (not yet taken place).</p> <p>She has applied for a grant from Novartis to make a patient information film on an aspect of treatment of hidradenitis suppurativa in the next 6 months, which was recently approved (no financial benefit to myself- costs purely to cover patient information film).</p>	03/10/2022	N/A	It was agreed that Ruth's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dr Ruth Lamb	Clinical Expert	Direct – Financial	<p>Ruth has received honoraria x1 for involvement in a virtual advisory board with Novartis (regarding discussion around problems with all/any current treatments in hidradenitis suppurativa with no particular reference to Secukinumab) on one occasion in the last 12 months (May 2022).</p> <p>She has also agreed provisionally to take part in a further global advisory panel for Novartis over the next 6 months (not yet taken place).</p> <p>She has applied for a grant from Novartis to make a patient information film on an aspect of treatment of hidradenitis suppurativa in the next 6 months, which was recently approved (no financial benefit to her -</p>	02/08/2023	N/A	It was agreed that Ruth's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			costs purely to cover patient information film)			